• Stat3 and NF-κB in Fyn-Driven Neurodegeneration

  2026-08-10

  This study develops a neural-specific zebrafish model showing that constitutively active Fyn drives dopaminergic neuron loss, mitochondrial abnormalities, and microglial inflammation. Transcriptomic and chemical inhibition experiments identify Stat3 as a downstream effector that acts synergistically with NF-κB, providing a mechanistic framework for studying Fyn-associated neurodegeneration.

• Biotin Azide for Mechanistic Wnt Assays

  2026-08-09

  Biotin Azide connects selective click labeling with mechanistic studies of Fzd5, cholesterol, and Wnt/β-catenin signaling. This guide explains how to design controls, choose assay formats, and interpret affinity-based evidence without overstating what the underlying cancer study demonstrated.

• Nadolol (SQ-11725): Designing Better PK Assays

  2026-08-08

  Nadolol (SQ-11725) offers a practical model for connecting beta-adrenergic pharmacology with transporter-aware pharmacokinetic analysis. This article applies disease-state and tissue-distribution insights from recent research to improve hypertension research, angina pectoris studies, and vascular headache research workflows.

• CRC Prognostic Biomarkers: TIMP1 and a Five-Gene Model

  2026-08-07

  Huang et al. integrated public transcriptomic datasets, network analysis, and Cox-based modeling to develop a five-gene colorectal cancer prognostic signature containing TIMP1, PCOLCE2, MEIS2, HDC, and CXCL13. External validation and siRNA experiments further prioritized TIMP1 as a candidate biomarker, although prospective clinical testing and deeper mechanistic studies are still needed.

• Strategic MMP Inhibition: GM 6001 (Galardin) in Translationa

  2026-08-07

  This thought-leadership article explores the transformative potential of GM 6001 (Galardin) as a broad spectrum matrix metalloproteinase inhibitor across neurodegeneration, tissue remodeling, and translational models. Integrating mechanistic insight, experimental validation, and strategic guidance, it highlights the pivotal role of MMP inhibition in preserving extracellular matrix integrity, with actionable advice for researchers navigating preclinical and translational challenges.

• Mouse Tissue Lysis Kit (K1038): Protocol and Best Practices

  2026-08-06

  The Mouse Tissue Lysis Kit (K1038) streamlines sample preparation for direct genotyping assays by enabling rapid lysis of mouse tissues and eliminating the need for conventional DNA extraction. It is intended for molecular biology research but should not be used for diagnostic or clinical purposes.

• BMX-IN-1: Unraveling BMX Kinase’s Role in Host-Pathogen and

  2026-08-06

  Explore the advanced applications of BMX-IN-1, a selective BMX kinase inhibitor, in dissecting cell signaling crucial for cancer and infectious disease research. This article uniquely connects BMX-IN-1’s mechanistic impact to emerging host-pathogen insights and optimized assay design.

• HyperScript III RT SuperMix: Precision qPCR for CRC Biomarke

  2026-08-05

  HyperScript III RT SuperMix for qPCR (with gDNA wiper) enables ultra-sensitive, high-fidelity detection of critical colorectal cancer biomarkers, even from low-input or high-GC content RNA. Its robust genomic DNA removal and optimized primer system empower researchers to confidently profile gene expression in complex, heterogeneous tumor samples.

• ECL Chemiluminescent Substrate Detection Kit: Ultra-Sensitiv

  2026-08-05

  The ECL Chemiluminescent Substrate Detection Kit (Enhanced) empowers researchers to achieve low-picogram protein detection with outstanding signal longevity and minimal background. Its robust compatibility and protocol simplicity make it the gold standard for high-precision western blot chemiluminescence detection, even in challenging experimental models such as BMSC signaling studies.

• Acetylspiramycin (Spiramycin B): Advanced Experimental Workf

  2026-08-04

  Acetylspiramycin (Spiramycin B) uniquely targets macrolide-resistant pathogens and offers immunomodulatory potential, enabling sophisticated experimental models. This guide clarifies robust workflows, troubleshooting strategies, and actionable protocol parameters for resistance and immune research.

• Boc-D-FMK: Pan-Caspase Inhibitor Workflows for Apoptosis Res

  2026-08-04

  Boc-D-FMK empowers apoptosis and inflammation research with robust, reproducible inhibition of caspase-driven cell death across diverse cellular and in vivo models. This article delivers stepwise protocols, troubleshooting strategies, and cross-study integration, making it an essential tool for scientists targeting cell death pathways or modeling disease.

• Palonosetron Hydrochloride in CINV: Implications for Colorec

  2026-08-03

  Ruhlmann and Herrstedt's review critically evaluates palonosetron—a next-generation 5-HT3 antagonist—for chemotherapy-induced nausea and vomiting (CINV) prevention, emphasizing its unique pharmacologic properties and clinical advantages over earlier agents. Their findings inform optimal antiemetic regimens in studies involving DNA-damaging drugs such as Irinotecan, with direct translational relevance for preclinical and clinical colorectal cancer research.

• Tolazoline as an α2-Adrenergic Receptor Antagonist: Applied

  2026-08-03

  Tolazoline empowers researchers to dissect α2-adrenergic receptor signaling and potassium channel modulation with precision, making it a cornerstone tool for islet function and airway smooth muscle studies. This guide demystifies optimized protocols, experimental enhancements, and troubleshooting insights for maximizing Tolazoline’s impact in translational pharmacology.

• AG-120 (Ivosidenib), mutant IDH1 inhibitor: Practical Lab So

  2026-08-02

  This article provides scenario-driven guidance for using AG-120 (Ivosidenib), mutant IDH1 inhibitor (SKU B7805) in cell-based assays targeting mutant IDH1-driven metabolic rewiring. By addressing common laboratory challenges and leveraging evidence-backed workflows, we demonstrate how SKU B7805 enhances reproducibility and translational impact for myeloid differentiation and 2-hydroxyglutarate reduction studies.

• Neuromedin S (rat): Technical Use in GPCR/G Protein Workflow

  2026-08-01

  Neuromedin S (rat) provides a chemically defined, endogenous agonist for consistent activation of neuromedin U receptor signaling in rat-based GPCR/G protein pathway research. It is intended strictly for in vitro and ex vivo laboratory workflows requiring reproducible peptide ligand input, and is not suitable for diagnostic, therapeutic, or non-rat model use.

445 records 8/30 page Previous Next First page 上5页 678910 下5页 Last page